XML 58 R3.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Income Statement [Abstract]        
Revenues $ 21,958 $ 23,562 $ 47,577 $ 57,615
Operating expenses:        
Research and development 36,288 28,810 107,593 81,612
General and administrative 14,918 10,993 46,633 32,381
Total operating expenses 51,206 39,803 154,226 113,993
Loss from operations (29,248) (16,241) (106,649) (56,378)
Interest and other income, net 1,887 3,398 6,729 6,708
Net loss (27,361) (12,843) (99,920) (49,670)
Net loss attributable to non-controlling interest (54) 0 (179) 0
Net loss to Sangamo Therapeutics, Inc. stockholders $ (27,307) $ (12,843) $ (99,741) $ (49,670)
Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in USD per share) $ (0.24) $ (0.13) $ (0.90) $ (0.52)
Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 115,710 101,725 110,837 95,165